Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal Isogenica, a leading innovator in VHH antibodies, is proud to unveil two significant collaborations using its synthetic VHH technology,...
University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech...
Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship Announcing a further collaboration with the Frederick National Laboratory for Cancer Research The relationship between Isogenica and...
Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display...
Isogenica and Frederick National Laboratory for Cancer Research team up to discover novel antibody therapeutics Announcing a new collaboration with the Frederick National Laboratory for Cancer Research UK-based antibody engineering experts Isogenica are proud...
Wellmarker Bio signs MoU with Isogenica for the development of multiple therapeutic assets The MoU will serve as a foundation for increased cooperation between the two companies Wellmarker Bio (WMBIO) and Isogenica today announced the signing of a Memorandum of...
